Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients.

Fibach E, Bianchi N, Borgatti M, Zuccato C, Finotti A, Lampronti I, Prus E, Mischiati C, Gambari R.

Eur J Haematol. 2006 Nov;77(5):437-41. Epub 2006 Aug 24.

PMID:
16939628
2.

Improved lung growth and function through hypoxia-inducible factor in primate chronic lung disease of prematurity.

Asikainen TM, Chang LY, Coalson JJ, Schneider BK, Waleh NS, Ikegami M, Shannon JM, Winter VT, Grubb P, Clyman RI, Yoder BA, Crapo JD, White CW.

FASEB J. 2006 Aug;20(10):1698-700. Epub 2006 Jun 28.

PMID:
16807366
3.

Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.

Bernhardt WM, Câmpean V, Kany S, Jürgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Günzler V, Amann K, Willam C, Wiesener MS, Eckardt KU.

J Am Soc Nephrol. 2006 Jul;17(7):1970-8. Epub 2006 Jun 8.

4.

Recombinant human erythropoietin: has treatment reached its full potential?

Fishbane S.

Semin Dial. 2006 Jan-Feb;19(1):1-4. Review.

PMID:
16423172
5.

Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production.

Safran M, Kim WY, O'Connell F, Flippin L, Günzler V, Horner JW, Depinho RA, Kaelin WG Jr.

Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):105-10. Epub 2005 Dec 22.

6.
7.

Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, Ratan RR.

J Biol Chem. 2005 Dec 16;280(50):41732-43. Epub 2005 Oct 13.

8.

Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins.

Brill-Almon E, Stern B, Afik D, Kaye J, Langer N, Bellomo S, Shavit M, Pearlman A, Lippin Y, Panet A, Shani N.

Mol Ther. 2005 Aug;12(2):274-82.

9.

Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsules.

Orive G, De Castro M, Ponce S, Hernández RM, Gascón AR, Bosch M, Alberch J, Pedraz JL.

Mol Ther. 2005 Aug;12(2):283-9.

10.

Human erythropoietin gene therapy for patients with chronic renal failure.

Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, Mei-Zahav C, Mizrachi S, Liberman Y, Iaina A, Kaplan E, Podjarny E, Zeira E, Harati M, Casadevall N, Shani N, Galun E.

Blood. 2005 Oct 1;106(7):2280-6. Epub 2005 Mar 29.

11.

Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.

Saunthararajah Y, DeSimone J.

Semin Hematol. 2004 Oct;41(4 Suppl 6):11-6. Review.

PMID:
15534852
12.

The regulated long-term delivery of therapeutic proteins by using antigen-specific B lymphocytes.

Takács K, Du Roure C, Nabarro S, Dillon N, McVey JH, Webster Z, Macneil A, Bartók I, Higgins C, Gray D, Merkenschlager M, Fisher AG.

Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16298-303. Epub 2004 Nov 1.

13.

A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells.

Bhanu NV, Trice TA, Lee YT, Gantt NM, Oneal P, Schwartz JD, Noel P, Miller JL.

Blood. 2005 Jan 1;105(1):387-93. Epub 2004 Sep 14.

14.

Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease.

Nakano Y, Imagawa S, Matsumoto K, Stockmann C, Obara N, Suzuki N, Doi T, Kodama T, Takahashi S, Nagasawa T, Yamamoto M.

Blood. 2004 Dec 15;104(13):4300-7. Epub 2004 Aug 24.

15.

Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.

Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM.

J Biol Chem. 2004 Sep 10;279(37):38458-65. Epub 2004 Jul 7.

16.

Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.

Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC.

Lancet. 2004 May 29;363(9423):1768-71.

PMID:
15172775
17.

Flow cytometric analysis of fetal hemoglobin in erythroid precursors of beta-thalassemia.

Amoyal I, Fibach E.

Clin Lab Haematol. 2004 Jun;26(3):187-93.

PMID:
15163316
18.

Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics.

Voutetakis A, Kok MR, Zheng C, Bossis I, Wang J, Cotrim AP, Marracino N, Goldsmith CM, Chiorini JA, Loh YP, Nieman LK, Baum BJ.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3053-8. Epub 2004 Feb 20.

19.

Autoimmune anemia in macaques following erythropoietin gene therapy.

Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Cherel Y, Casadevall N, Samulski RJ, Moullier P.

Blood. 2004 May 1;103(9):3303-4. Epub 2004 Jan 22.

20.

Erythropoietin gene therapy leads to autoimmune anemia in macaques.

Gao G, Lebherz C, Weiner DJ, Grant R, Calcedo R, McCullough B, Bagg A, Zhang Y, Wilson JM.

Blood. 2004 May 1;103(9):3300-2. Epub 2003 Dec 24.

Supplemental Content

Support Center